Drugs Misuse Act 1986 Drugs Misuse Regulation 1987 Part 1 Preliminary pt hdg ins 1996 SL No. 309 s 4 1 Short title This regulation may be cited as the Drugs Misuse Regulation 1987 . 2 Dictionary The dictionary in schedule 9 defines particular words used in this regulation. s 2 prev s 2 amd 1996 SL No. 309 s 5 (1); om R2 (see RA s 37) pres s 2 (prev s 4) sub 1998 SL No. 348 s 3 (2) renum 2002 No. 255 s 3 def occupier’s notice reloc to sch 9 1998 SL No. 348 s 3 (1) def record of proceedings reloc to sch 9 1998 SL No. 348 s 3 (1) def search warrant reloc to sch 9 1998 SL No. 348 s 3 (1) def supply ins 1996 SL No. 309 s 5 (3) om 1998 SL No. 348 s 3 (2) def the Act sub 1989 reg pubd gaz 6 May 1989 pp 230–1 om 1996 SL No. 309 s 5 (2) Part 2 Syringes and dangerous drugs disposal procedures pt hdg prev pt 2 hdg ins 1996 SL No. 309 s 6 om 2002 SL No. 255 s 4 pres pt 2 hdg (prev pt 3 hdg) ins 1996 SL No. 309 s 11 renum 2002 SL No. 255 s 5 (1) 3 Prescribed procedures for the disposal of hypodermic syringes and needles For the purposes of section 10 (4A) of the Act, the prescribed procedures for the disposal of a hypodermic syringe or needle are—

(a) by placing the hypodermic syringe or needle in a rigid wall, puncture resistant container and that container is sealed or securely closed in such a manner that its contents are incapable of causing injury to any person; or

(b) by giving the hypodermic syringe or needle to a person who is a medical practitioner, pharmacist or person or a member of a class of persons referred to as authorised in section 10 (3) of the Act.

s 3 ins reg pubd gaz 6 May 1989 pp 230–1 renum 2002 SL No. 255 s 5 (2) amd 2009 SL No. 99 s 3 4 Prescribed procedure for disposal of dangerous drugs For the purposes of section 125 of the Act, the prescribed procedure for the disposal of a thing is—

(a) in the case where the thing is a trace amount of a dangerous drug contained in a hypodermic syringe or needle, by disposing of the hypodermic syringe or needle in accordance with the procedures prescribed in section 3; or

(b) in any other case, at the first reasonable opportunity, by giving—

(i) such thing; and

(ii) where such thing is contained in a hypodermic syringe or needle, such syringe or needle;

to an inspector appointed under the Health Act 1937 , section 137. s 4 (prev s 10) ins reg pubd gaz 6 May 1989 pp 230–1 renum 2002 SL No. 255 s 5 (2) amd 2006 SL No. 71 s 4; 2008 Act No. 4 s 34; 2009 SL No. 99 s 4 Part 3 Controlled substances pt hdg (prev pt 4 hdg) ins 1996 SL No. 309 s 12 renum 2002 SL No. 255 s 5 (1) 5 Other act that is a relevant transaction—Act, s 43C (b) Any act by which a controlled substance is supplied by a person, in or in connection with the person’s business, to anyone else is a relevant transaction for the supply of a controlled substance. Example— A and B are partners in a chain of pharmacies. They make cold tablets to sell in the pharmacies by compounding ephedrine (a controlled substance) with other substances. The partners sell some of the left over ephedrine to a pharmaceutical research company and give the rest away. Both the sale and gift of ephedrine are relevant transactions. Editor’s note— Under section 43A of the Act— supply means give, distribute, sell or supply. s 5 prev s 5 amd 1996 SL No. 309 s 7 om 2002 SL No. 255 s 4 pres s 5 (prev s 11) ins 1996 SL No. 309 s 12 renum 2002 SL No. 255 s 5 (2) 6 Documents and proof of identity required for supply of a controlled substance or controlled thing—Act, s 43D (1) (a) (1) This section applies to a person who supplies a controlled substance or controlled thing under a relevant transaction to anyone else (a recipient). (2) The person must, before supplying the substance or thing, obtain from the recipient a document (an end user declaration) showing the following information—

(a) the recipient’s name and address, and if the recipient purports to obtain the substance or thing for another person, the other person’s name and address;

(b) details of the official document produced by the recipient under subsection (3) as evidence of the recipient’s identity;

(d) the name and quantity of the substance or thing to be supplied;

(e) if a thing is supplied—the serial number or unique identifier of the thing;

(f) the date on which the substance or thing is to be supplied;

(g) the purpose for which the substance or thing is to be supplied.

(3) If the recipient is an individual, the person must, before supplying the substance or thing, require the recipient to produce an official document containing the recipient’s photograph (for example, a passport or driver licence) as evidence of the recipient’s identity. (4) The person must, immediately the person supplies the substance or thing under the transaction, make an invoice for the supply of the substance or thing showing the following details—

(a) the recipient’s name and address;

(b) the recipient’s order number for the supply of the substance or thing;

(d) the name and quantity of the substance or thing supplied.

Maximum penalty for subsection (4)—20 penalty units. s 6 prev s 6 amd 1996 SL No. 309 s 8 om 2002 SL No. 255 s 4 pres s 6 (prev s 12) ins 1996 SL No. 309 s 12 renum 2002 SL No. 255 s 5 (2) amd 2008 Act No. 4 s 35; 2009 SL No. 99 s 5 6A End user declaration to be given to commissioner of police service—Act, s 43D (1) (d) (1) This section applies to a person who supplies a controlled substance or controlled thing under a relevant transaction to anyone else (the recipient). (2) The person must, as soon as practicable after obtaining from the recipient the end user declaration mentioned in section 6 (2), give a copy of the end user declaration to the commissioner of the police service. s 6A ins 2008 Act No. 4 s 36 7 Details about supply of controlled substance or controlled thing to be recorded in register (1) The following details about a relevant transaction for the supply of a controlled substance or controlled thing must be recorded in the register—

(a) the name and address of the recipient and, if the recipient purports to obtain the substance or thing for another person, the other person’s name and address;

(b) the recipient’s order number for the supply of the substance or thing;

(d) if the recipient is—

(i) a company—its Australian Company Number; or

(ii) an individual—the type of official document produced under section 6 (3) and the following details about the document—

(A) who issued it;

(B) its serial number or other identifying number or mark;

(e) the name and quantity of the substance or thing supplied;

(f) the date the substance or thing was supplied;

(g) the purpose for which the substance or thing was supplied.

(2) The details must be recorded in the register as soon as practicable, but in no case later than 7 days, after the day the person supplied the substance or thing under the transaction. (3) Nothing in this section prevents the keeping of a single register for the Act and another Act if—

(a) the keeping of the single register is not contrary to the other Act; and

(b) the details recorded under subsection (1) are easily identifiable in the single register.

Note— See section 43D (1) (c) of the Act for the requirement to keep the register. s 7 prev s 7 sub reg pubd gaz 17 December 1988 pp 2214–15 amd 1996 SL No. 309 s 9 om 2002 SL No. 255 s 4 pres s 7 (prev s 13) ins 1996 SL No. 309 s 12 renum 2002 SL No. 255 s 5 (2) amd 2008 Act No. 4 s 37; 2012 SL No. 92 s 19 8 Details about loss or theft of controlled substance or controlled thing to be recorded in register The following details of the reporting to a police officer of the loss or theft of a controlled substance or controlled thing must be recorded in the register—

(a) the day and place the report was made;

(b) the name and registered number of the officer to whom the report was made;

s 8 prev s 8 om 1996 SL No. 309 s 10 pres s 8 (prev s 14) ins 1996 SL No. 309 s 12 renum 2002 SL No. 255 s 5 (2) amd 2008 Act No. 4 s 38 9 Keeping of register, invoice and other documents (1) This section applies to the register and other documents mentioned in the Act, section 43D (1) and the invoice required under section 6 (4). (2) A person who supplies a controlled substance or controlled thing under a relevant transaction must keep the register, documents or invoice—

(a) at the principal or only place in Queensland where the person engages in relevant transactions; and

(b) for 2 years from the day the person supplied the substance or thing under the transaction.

s 9 (prev s 15) ins 1996 SL No. 309 s 12 renum 2002 SL No. 255 s 5 (2) amd 2008 Act No. 4 s 39 Part 4 Commercial production of industrial cannabis pt hdg (prev pt 5 hdg) ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 Division 1 Preliminary div hdg ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 10 Operation of pt 4 and schs 7 and 8 (1) Divisions 3 to 7 state activities stated persons are authorised to perform for the purposes of part 5B of the Act. (2) Schedule 7 states conditions applying to particular persons who perform activities stated in divisions 4, 5, 6 and 7. (3) If a word used in this part, schedule 7 or schedule 8 is not defined in the dictionary but is defined for part 5B of the Act, the word has the same meaning as in that part, unless a contrary intention appears. Note— See section 46 of the Act for definitions for pt 5B of the Act. s 10 ins 2002 SL No. 255 s 6 amd 2012 SL No. 92 s 20 Division 2 Certified cannabis seed div hdg ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 11 Certifying cannabis seed (1) The way seed originating in Queensland is to be certified for the definition certified cannabis seed in section 46 of the Act is stated in the Industrial Cannabis THC Seed Certification Code of Practice approved by the chief executive by gazette notice. Editor’s note— The code is a departmental document and is published by the department. A copy of the code may be obtained or inspected without charge from the department’s head office at 80 Ann Street, Brisbane during normal business hours. The department’s internet site is at <www.daff.qld.gov.au> and the code is also available there. (2) The way cannabis seed originating in another State or a foreign country (imported seed) is certified for the definition certified cannabis seed in section 46 of the Act is stated in subsection (3). (3) The seed must be in a package that—

(a) has a document attached to it certifying that the seed—

(i) has been certified in accordance with a recognised quality assurance program; and

(ii) if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of not more than 0.5%; and

(b) describes the contents of the package as seed that, if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of not more than 0.5%.

s 11 ins 2002 SL No. 255 s 6 Division 3 Carriers div hdg ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 12 Application of div 3 This division applies to a carrier only if the carrier is engaged or employed by any of the following to transport consigned cannabis—

(a) a category 1 or category 2 researcher;

(b) a grower;

(d) an inspector;

(e) a seed supplier.

s 12 ins 2002 SL No. 255 s 6 13 Supply (1) The carrier is authorised to transport consigned cannabis and give it to the person to whom it is consigned. (2) The authorisation—

(a) is for the time necessary for the carrier to transport the consigned cannabis and give it to the person to whom it is consigned; and

(b) has effect only while the carrier is acting in accordance with the terms of the carrier’s engagement or employment.

s 13 ins 2002 SL No. 255 s 6 14 Possession (1) The carrier is authorised to possess consigned cannabis for the time necessary for the carrier to transport it to the person to whom it is consigned and give it to the person. (2) The authorisation has effect only while the carrier is acting in accordance with the terms of the carrier’s engagement or employment. s 14 ins 2002 SL No. 255 s 6 Division 4 DPI researchers div hdg ins 2002 SL No. 255 s 6 15 Supply A DPI researcher is authorised—

(a) to supply class A research cannabis plants and seed to another DPI researcher or a category 1 researcher; and

(b) to supply class B research cannabis plants and seed to another DPI researcher or a category 1 or category 2 researcher; and

(c) to supply class A and class B research cannabis seed to a grower for use, under the DPI researcher’s supervision, as part of a field trial the DPI researcher is conducting on land owned or leased by the grower; and

(d) to supply industrial cannabis seed to any of the following—

(i) a grower;

(ii) a category 1 or category 2 researcher;

(iii) another DPI researcher;

(iv) the owner or operator of a facility at which industrial cannabis seed may be denatured;

(v) the owner or operator of a facility where processed cannabis is, or is to be, used for manufacturing a manufactured product for sale by wholesale or retail; and

(e) to supply class A or class B research cannabis seed or industrial cannabis seed to a person in another State who is authorised under the law of that State to possess cannabis seed that, if grown, will produce plants with a THC concentration in their leaves and flowering heads that the person in the other State may possess; and

(f) to supply class A or class B research cannabis plants, industrial cannabis plants or processed cannabis to an analyst; and

(g) to supply processed cannabis to the owner or operator of a facility where processed cannabis is used for manufacturing a manufactured product for sale by wholesale or retail.

s 15 ins 2002 SL No. 255 s 6 16 Production A DPI researcher is authorised to produce, for use in plant breeding programs for developing new commercial strains of industrial cannabis—

(a) industrial cannabis plants and seed; and

(b) class A and class B research cannabis plants and seed.

s 16 ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 17 Possession A DPI researcher is authorised to possess any of the following for a purpose mentioned in section 15 or 16—

(a) industrial cannabis plants and seed;

(b) class A and class B research cannabis plants and seed;

s 17 ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 Division 5 Inspectors div hdg ins 2002 SL No. 255 s 6 18 Supply An inspector is authorised—

(a) to supply industrial cannabis plants, class A or class B research cannabis plants or processed cannabis to an analyst to analyse the THC concentration in any of them; and

(b) if the inspector is given industrial cannabis plants or seed or class A or class B research cannabis plants or seed for delivery to a particular person who is lawfully entitled to possess the plants or seed—to supply the plants or seed to the person.

s 18 ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 19 Possession An inspector is authorised—

(a) to possess industrial cannabis plants, class A or class B research cannabis plants or processed cannabis given to the inspector for delivery to an analyst to analyse the THC concentration in the plants or processed cannabis; and

(b) to possess industrial cannabis plants or seed or class A or class B research cannabis plants or seed given to the inspector for delivery to a person lawfully entitled to possess the plants or seed.

s 19 ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 Division 6 Seed suppliers div hdg ins 2002 SL No. 255 s 6 20 Supply A seed supplier is authorised to supply industrial cannabis seed to any of the following—

(a) a category 1 or category 2 researcher;

(b) a grower;

(d) a person in another State who is authorised under the law of that State to possess cannabis seed that, if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads the person in the other State may possess;

(e) if the seed supplier holds a licence under the Customs Act 1901 (Cwlth) authorising the seed supplier to export cannabis—a person in a foreign country who is authorised under the law of the country to possess the seed.

s 20 ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 21 Possession A seed supplier is authorised to possess industrial cannabis seed for the purpose of supplying it to a person mentioned in section 20. s 21 ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 Division 7 Other persons div hdg ins 2002 SL No. 255 s 6 22 Denaturer (1) The owner or operator of a facility where industrial cannabis seed may be denatured under an agreement or arrangement with a licensee or another person authorised under this part to produce industrial cannabis seed (denaturer), is authorised to possess industrial cannabis seed supplied to the owner or operator, but only for the purpose of denaturing the seed. (2) A denaturer is authorised to supply denatured seed to a person who is authorised to possess processed cannabis. s 22 ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 23 Manufacturer The owner or operator of a facility where processed cannabis is used for manufacturing a manufactured product for sale by wholesale or retail is authorised to possess processed cannabis for using it for manufacturing a manufactured product. s 23 ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 24 Analyst (1) An analyst is authorised to possess—

(a) standard THC material to calibrate an analytical instrument used for analysing a substance to determine its THC concentration; and

(b) if an authorised person engages or employs the analyst to analyse a substance to determine its THC concentration—the substance for the purpose of the analysis.

(2) In this section— authorised person means any of the following—

(a) a category 1 or category 2 researcher;

(b) a grower;

(d) an inspector.

substance means a substance that an authorised person reasonably believes to be any of the following—

(a) industrial cannabis plants;

(b) class A or class B research cannabis plants;

s 24 ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 25 Family members (1) A person who is a member of the immediate family of a licensee is authorised to produce, possess or supply a substance if—

(a) the licensee is authorised to produce, possess or supply the substance under the Act; and

(b) the person’s production, possession or supply of the substance is necessary for, or incidental to the licensee’s production, possession or supply of the substance.

(2) In this section— substance means any of the following—

(a) class A research cannabis plants;

(b) class A research cannabis seed;

(d) class B research cannabis seed;

(e) industrial cannabis plants;

(f) industrial cannabis seed;

(g) processed cannabis.

s 25 ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 26 Employees of authorised persons (1) An employee of an authorised person is authorised to produce, possess, supply or transport a substance if—

(a) under the Act, the authorised person is authorised to produce, possess, supply or transport the substance; and

(b) the employee’s production, possession, supply or transportation of the substance is necessary for, or incidental to, performing the employee’s employment or engagement.

(2) In this section— authorised person means any of the following—

(a) a licensee;

(b) a carrier;

(d) an inspector;

(e) a seed supplier;

(f) a denaturer;

(g) a manufacturer;

(h) an analyst.

employee includes agent. substance means any of the following—

(a) class A research cannabis plant;

(b) class A research cannabis seed;

(d) class B research cannabis seed;

(e) industrial cannabis plant;

(f) industrial cannabis seed;

(g) processed cannabis.

s 26 ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 Division 8 Other provisions div hdg ins 2002 SL No. 255 s 6 27 Recognition as seed supplier (1) A person may apply in writing to the chief executive for recognition as a seed supplier. (2) The chief executive must recognise the person as a seed supplier if the chief executive is satisfied the person—

(a) for trade or commerce, sells or otherwise provides seeds to someone else; and

(b) for selling or providing the seed, has a current recognised quality assurance program that conforms to an industry standard or code of practice; and

(3) The chief executive must give a person recognised as a seed supplier written notice of the recognition. (4) The recognition notice must state—

(a) the person’s recognition number as a seed supplier; and

(b) the date the recognition ends, which must not be longer than 3 years after the date of the notice.

(5) The recognition is not transferable. s 27 ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 28 Licence fees (1) The fee payable on application for a licence under the Act, part 5B is $439.15. (2) The fee payable on application for the renewal of a licence is $175.70. s 28 ins 1998 SL No. 348 s 4 sub 2002 SL No. 255 s 6 amd 2004 SL No. 231 s 14; 2005 SL No. 268 s 14; 2006 SL No. 267 s 14; 2007 SL No. 232 s 14; 2008 SL No. 314 s 14; 2009 SL No. 176 s 17; 2010 SL No. 268 s 7; 2011 SL No. 110 s 14; 2012 SL No. 92 s 21; 2013 SL No. 102 s 16; 2014 SL No. 113 s 16; 2015 SL No. 57 s 16 29 Licence conditions—Act, s 64 (1) The conditions in schedule 8 are prescribed for section 64 (3) of the Act. (2) Unless otherwise expressly stated, the conditions apply to all licensees. s 29 ins 2001 SL No. 52 s 3 sub 2002 SL No. 255 s 6 Part 5 Transitional provisions pt hdg (prev pt 6 hdg) ins 2001 SL No. 174 s 3 renum 2002 SL No. 255 s 5 (1) amd 2002 SL No. 368 s 3 30 Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2001 (1) To remove doubt, it is declared that this regulation, as in force immediately before the commencement of the Drugs Misuse Amendment Regulation (No. 2) 2001 (the amending regulation), continues to apply in relation to an offence against the Act committed before the commencement of the amending regulation. (2) Proceedings for an offence against the Act committed before the commencement of the amending regulation may be continued or started as if the amending regulation had not been made. s 30 ins 2001 SL No. 174 s 3 31 Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2002 (1) To remove doubt, it is declared that this regulation, as in force immediately before the commencement of this section, continues to apply in relation to an offence against the Act committed before the commencement of this section. (2) Proceedings for an offence against the Act committed before the commencement of this section may be continued or started as if the Drugs Misuse Amendment Regulation (No. 2) 2002 had not been made. s 31 ins 2002 SL No. 368 s 4 Schedule amd reg pubd gaz 17 December 1988 pp 2214–5 om 1996 SL No. 309 s 13 Schedule 1 Dangerous drugs sections 4, definition dangerous drug , 4A, 5, 6, 8, 8A, 9 and 134 Part 1 Non-steroid drugs

Amphetamine

Cocaine

Heroin

Lysergide

Methylamphetamine

3,4-Methylenedioxymethamphetamine (MDMA)

Paramethoxyamphetamine (PMA)

Paramethoxymethamphetamine (PMMA)

Phencyclidine

Part 2 Steroid drugs

Androisoxazole

Androstenediol

Atamestane

Bolandiol

Bolasterone

Bolazine

Boldenone (dehydrotestosterone)

Bolenol

Bolmantalate

Calusterone

Chlorandrostenolone

4-Chloromethandienone

Chloroxydienone

Chloroxymesterone (dehydrochloromethyltestosterone)

Clostebol (4-chlorotestosterone)

Danazol

Dehydroepiandrosterone (DHEA)

Dihydrolone

Dimethandrostanolone

Drostanolone

Enestebol

Epitiostanol

Ethyldienolone

Ethylestrenol

Fluoxymesterone

Formebolone (formyldienolone)

Furazabol

4-Hydroxy-19-nortestosterone

Hydroxystenozol

Mebolazine

Mepitiostane

Mesabolone

Mestanolone (androstalone)

Mesterolone

Methandienone

Methandriol

Methenolone

Methylclostebol

Methyltestosterone

Methyltrienolone

Metribolone

Mibolerone

Nandrolone

Norandrostenolone

Norbolethone

Norclostebol

Norethandrolone

Normethandrone

Ovandrotone

Oxabolone

Oxandrolone

Oxymesterone

Oxymetholone

Prasterone

Propetandrol

Quinbolone

Silandrone

Stanolone

Stanozolol

Stenbolone

Testosterone, other than in implant preparations for growth promotion in animals

Thiomesterone (tiomesterone)

Tibolone

Trenbolone (trienbolone, trienolone), other than in implant preparations for use in animals

Trestolone

Any other anabolic and androgenic steroidal agent

sch hdg ins 1997 SL No. 459 s 3(1) amd 2009 SL No. 99 s 6; 2013 SL No. 41 s 3(1) sch 1 (prev 1986 Act No. 36 sch 1) amd 1996 Act No. 49 s 15 reloc 1996 Act No. 49 s 21 amd 1997 SL No. 459 s 3(2); 2001 SL No. 174 s 4; 2002 SL No. 255 s 7(1); 2008 Act No. 4 s 40; 2013 SL No. 41 s 3(2); 2014 Act No. 42 ss 23, 24 Schedule 2 Dangerous drugs sections 4, definition dangerous drug , 4A, 5, 6, 8, 8A, 9 and 134 of the Act Acetorphine Acetyl-alpha-methylfentanyl Acetyldihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of acetyldihydrocodeine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of acetyldihydrocodeine.

Acetylmethadol Acetylmorphine N-(1-Adamantyl)-1-pentyl-indazole-3-carboxamide (APINACA or AKB48) Alfentanil Alkoxyamphetamines and bromo-substituted alkoxyamphetamines other than where separately specified Alkoxyphenethylamines and alkyl-substituted alkoxyphenethylamines other than where separately specified Alkylthioamphetamines and substituted alkylthioamphetamines other than where separately specified Allobarbital Allylprodine Alphacetylmethadol Alphaethyltryptamine Alphameprodine Alphamethadol Alpha-Methylfentanyl Alpha-Methylthiofentanyl Alphamethyltryptamine (AMT) Alphaprodine Alpha-Pyrrolidinovalerophenone (alpha-PVP) Alphenal Alprazolam 2-Aminoindane 6-(2-Aminopropyl)benzofuran (6-APB) Aminorex Amobarbital Anileridine Aprobarbital Bambuterol Barbital Barbituric acid and any 5,5 disubstituted derivatives of barbituric acid, whether or not further substituted at position 1 of the ring Benzethidine Benzphetamine (N-Benzyl-N-alpha-dimethylphenethylamine) Benzylmorphine N-Benzylpiperazine (BZP) Betacetylmethadol Beta-Hydroxy-3-methylfentanyl Beta-Hydroxyfentanyl Betameprodine Betamethadol Betaprodine Bezitramide Bromazepam 4-Bromo-2,5-dimethoxyamphetamine (DOB, 4-Bromo-DMA) 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) Bromo-Dragonfly (1-(8-bromobenzo[1,2-b;4,5-b’]difuran-4-yl)-2-aminopropane) Brotizolam Bufotenine (5-Hydroxy-N,N-dimethyltryptamine) Buprenorphine Butabarbital Butalbital Butallylonal Butethal Butorphanol 1-Butyl-3-(2-methoxybenzoyl)indole (RCS-4(C4) 2-methoxy isomer) 1-Butyl-3-(1-naphthoyl)indole (JWH-073) Camazepam Cannabinoids other than tetrahydrocannibinols Cannabis [3-(3-Carbamoylphenyl)phenyl] N-cyclohexylcarbamate (URB-597) Carfentanil Catha edulis (Khat) Cathine Cathinone Chlordiazepoxide 4-Chloro-2,5-dimethoxyamphetamine (DOC) Chlorphentermine (4-chloro-alpha,alpha-dimethylphenethylamine) Clenbuterol Clobazam Clonazepam Clonitazene Clorazepate Clotiazepam Cloxazolam Coca leaf Codeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 30mg or less of codeine per dosage unit; or

(b) in undivided preparations containing 1% or less of codeine.

Codeine-N-Oxide Codoxime 4-Cyano-2-dimethylamino-4,4-diphenylbutane 4-Cyano-1-methyl-4-phenylpiperidine Cyclobarbital Cyclohexyl [1,1'-biphenyl]-3-ylcarbamate (URB-602) Cyclopal 1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (RCS-8) Delorazepam Desomorphine Desoxypipradrol (2-DPMP) Dextromoramide Dextropropoxyphene Diampromide Diazepam Diethylpropion Diethylthiambutene N,N-Diethyltryptamine Difenoxin other than in preparations containing 0.5mg or less of difenoxin and a quantity of atropine sulphate equivalent to not less than 5% of the dose of difenoxin per dosage unit Dihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of dihydrocodeine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of dihydrocodeine.

Dihydroetorphine Dihydromorphine Dimenoxadol Dimepheptanol 2,5-Dimethoxyamphetamine (2,5-DMA) 2,5-Dimethoxy-4-ethylamphetamine (DOET) 2,5-Dimethoxy-4-ethylphenethylamine (2C-E) 2,5-Dimethoxy-4-ethylthiophenethylamine (2C-T-2) 2,5-Dimethoxy-4-iodoamphetamine (DOI) 2,5-Dimethoxy-4-methylamphetamine (DOM) 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) Dimethylamino-1,2-diphenylethane N,N-Dimethylamphetamine 1,3-Dimethylamylamine (DMAA or methylhexanamine) 3-(1,2-Dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6-H-dibenzo(b,d)pyran 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210) N,N-dimethyl-3,4-methylenedioxyamphetamine (MDDM) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP 47, 497 C8 homologue) Dimethylthiambutene N,N-Dimethyltryptamine Dioxaphetyl butyrate Diphenoxylate other than in preparations containing 2.5mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to not less than 1% of the dose of diphenoxylate per dosage unit Dipipanone Drotebanol Ecgonine, its esters and derivatives which are convertible to ecgonine and cocaine Ephedra spp. Ephedrine Erythropoietin (EPO) Erythroxylum coca Erythroxylum nova-granatense Estazolam Ethchlorvynol Ethinamate 4-Ethoxyamphetamine 4-Ethoxy-2,5-dimethoxyamphetamine (MEM) N-Ethylamphetamine Ethylcathinone (2-ethylamino-1-phenyl-propan-1-one) Ethyl Loflazepate Ethylmethylthiambutene Ethylmorphine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of ethylmorphine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of ethylmorphine.

N-Ethyl-1-phencyclohexylamine Etonitazene Etorphine Etoxeridine Etryptamine Fencamfamin Fenethylline (Theophylline-ethylamphetamine) Fenoterol Fenproporex (N-2-Cyanoethylamphetamine) Fentanyl Fludiazepam Flunitrazepam 4-Fluoroamphetamine 4-Fluoromethamphetamine 2-Fluoromethcathinone 3-Fluoromethcathinone 4-Fluoromethcathinone 1-(5-Fluoropentyl)-3-(1-adamantylamido)indole (STS-135) (1-(5-Fluoropentyl)-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl) methanone (XLR-11; 5-Fluoro UR-144) 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694) 1-(5-Fluoropentyl)-3-(4-methyl-1-naphthoyl)indole (5-Fluoro JWH-122) 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM-2201) Flurazepam Formoterol other than in metered aerosols for inhalation Furethidine Gamma hydroxybutyric acid (GHB) Glutethimide Growth Hormone (hGH) Halazepam Haloxazolam Harmaline Harmalol Heptabarbital Hexethal Hexobarbital 1-Hexyl-3-(1-naphthoyl)indole (JWH-019) Hydrocodone Hydromorphinol Hydromorphone N-(2-Hydroxyethyl)-alpha-methylbenzeneethanamine N-Hydroxy-3,4-methylenedioxyamphetamine (N-Hydroxy-MDA) 4-Hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET) Hydroxypethidine 5-Hydroxy tryptophan (5-HTP) other than in preparations containing 100mg or less of 5-HTP per dosage unit Insulin-like Growth Factor-1 (IGF-1) 4-Iodo-2,5-dimethoxyphenethylamine (2C-I) Isomethadone Ketamine Ketazolam Ketobemidone Lefetamine (N,N-Dimethyl-alpha-phenylphenethylamine) Levomethorphan Levophenacylmorphan Levorphanol Lophophora (peyote) Loprazolam Lorazepam Lormetazepam Levomoramide Lysergamide and N-alkyl derivatives of lysergamide other than lysergide Lysergic acid Mazindol Mecloqualone (3-(2-Chlorophenyl)-2-methyl-4(3H)-quinazolinone) Medazepam Mefenorex (N-(3-Chloropropyl)-alpha-methylphenethylamine) Mephobarbital Meprobamate Mescaline (3,4,5-Trimethoxyphenethylamine) Mesocarb (3-(Alpha-methylphenethyl)-N-(phenylcarbamoyl)sydnone imine) Metazocine Methabarbital Methadone Methaqualone (2-Methyl-3-(2-methylphenyl)-4(3H)-quinazolinone) Methcathinone Methiopropamine Methoxetamine 5-Methoxy alphamethyltryptamine (5-MeO-AMT) N-(2-Methoxybenzyl)-2,5-dimethoxy-4-bromophenethylamine (25B-NBOMe) N-(2-Methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) N-(2-Methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (25I-NBOMe) 5-Methoxy-N,N-diallyltryptamine (5-MeO-DALT) 5-Methoxy dimethyltryptamine 5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) 5-Methoxy-3,4-methylenedioxyamphetamine (MMDA) 2-(4-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone (JWH-201) 4-Methoxyphenyl-(1-butyl-1H-indol-3-yl)-methanone (RCS-4 (C4)) 2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250) 2-(3-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-302) Methyl (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-Acetoxy-6a,10b-dimethyl-4,10-dioxo-dodecahydro-2-(3-furyl)-2H-naphtho{2,1-c]pyran-7-caboxylate (Salvinorin A) 2-Methylamino-1-(3,4-methylenedioxyphenyl) butane (MBDB) 2-Methylamino-1-phenyl-1-propanone 4-Methylaminorex Methyldesorphine Methyldihydromorphine 5,6-Methylenedioxy-2-aminoindane (MDAI) 3,4-Methylenedioxyamphetamine (MDA) 3,4-Methylenedioxyethylamphetamine (MDEA) 1-(3,4-Methylenedioxy)methcathinone (methylone) 3,4-Methylenedioxypyrovalerone (MDPV) 4-Methylethylcathinone (4-MEC) 3-Methylfentanyl 2-Methyl-3-morpholino-1, 1-diphenylpropane carboxylic acid 4-Methylmethcathinone Methylphenidate Methylphenobarbital 1-[1-(4-Methylphenyl)cyclohexyl]piperidine 1-Methyl-4-phenylpiperidine-4-carboxylic acid 1-[(N-Methylpiperidin-2-yl)methyl]-3-(1-adamantoyl)indole (AM-1248) 1-[(N-Methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole (AM-2233) 1-[(N-Methylpiperidin-2-yl)methyl]-3-(4-methyl-1-naphthoyl)indole (MAM-1220) 1-[(N-Methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)indole (AM-1220) N-Methyl-3-piperidyl benzilate 4-Methylthioamphetamine (4-MTA) 3-Methylthiofentanyl Methyprylon Metopon Midazolam Mitragyne speciosa (kratom) Moramide Morpheridine Morphine Morphine methobromide Morphine-N-oxide 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) Myrophine Nabilone Nalbuphine Nalorphine Naphthylpyrovalerone (Naphyrone) Nicocodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of nicocodine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of nicocodine.

Nicodicodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of nicodicodine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of nicodicodine.

Nicomorphine Nimetazepam Nitrazepam Noracymethadol Norcodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of norcodeine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of norcodeine.

Nordazepam Norlevorphanol Normethadone Normorphine Norpipanone Opium Oxazepam Oxazolam Oxycodone Oxymorphone Papaver bracteatum Papaver orientale Papaver somniferum other than the seed thereof which seed has been rendered sterile Para-Fluorofentanyl Parahexyl Pemoline Pentazocine Pentobarbital 1-Pentyl-3-(1-adamantoyl)indole (AB-001) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) 1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210) (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) 1-Pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4) 1-Pentyl-3-(2-methoxybenzoyl)indole (RCS-4 (2-methoxy isomer)) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018) Pethidine Phenadoxone Phenampromide Phenazepam Phenazocine Phendimetrazine Phenmetrazine Phenobarbital Phenomorphan Phenoperidine Phentermine (alpha,alpha-Dimethylphenethylamine) 1-(1-Phenylcyclohexyl)pyrrolidine (PCPy) Phenylmethylbarbituric Acid 1-[1-(Phenylmethyl)cyclohexyl]piperidine 4-Phenylpiperidine-4-carboxylic acid ethyl ester 1-Phenyl-N-propylcyclohexanamine Pholcodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of pholcodine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of pholcodine.

Phthalimidopropiophenone Piminodine Pinazepam Pipradol Piritramide Pravadoline (WIN 48098) Prazepam Probarbital Proheptazine Propallylonal Properidine Propiram Propylhexedrine (1-cyclohexyl-2-methylaminopropane) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015) N-Propyl-3,4-methylenedioxyamphetamine (MDPR) Psilocin (4-Hydroxy-N,N-dimethyltryptamine) Psilocybin (O-Phosphoryl-4-hydroxy-N,N-dimethyltryptamine) Pyrovalerone Quazepam Racemethorphan Racemoramide Racemorphan Remifentanil Reproterol 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol (CP 47,497) Salbutamol other than in metered aerosols or dry powder or capsules of dry powder for inhalation Salvia divinorum Secobarbital Sigmodal Somatotropin Sufentanil Talbutal Temazepam Terbutaline, other than in metered aerosols for inhalation Testolactone Tetrahydrocannabinols including their alkyl homologues other than where separately specified; and their corresponding carboxylic acids Tetrazepam Thebacon Thebaine Thialbarbital Thiamylal 1-(1-(2-Thienyl)cyclohexyl)piperidine (TCP) Thiobarbituric Acid Thiofentanyl Thiopental Tilidine Triazolam 1-(3-Trifluoromethylphenyl) piperazine (TFMPP) Trimeperidine 2,4,5-Trimethoxyamphetamine 3,4,5-Trimethoxyamphetamine Vinbarbital Vinylbital Zeranol Zipeprol (1-(2-Methoxy-2-phenylethyl))-4-(2-hydroxy-3-methoxy-3- phenylpropyl) piperazine Zolazapam Zolpidem sch hdg ins 1997 SL No. 459 s 4(1) amd 2009 SL No. 99 s 6; 2013 SL No. 41 s 4(1) sch 2 (prev 1986 Act No. 36 sch 2) amd 1987 Act No. 53 s 11; 1989 Act No. 34 s 22; 1996 Act No. 49 s 16 reloc 1996 Act No. 49 s 21 amd 1997 SL No. 303 s 3; 1997 SL No. 459 s 4(2)–(3); 1999 SL No. 41 s 3; 2001 SL No. 174 s 5; 2001 SL No. 249 s 3; 2002 SL No. 255 s 7(1); 2002 SL No. 368 s 5; 2003 SL No. 374 s 3; 2005 SL No. 7 s 3 sub 2008 Act No. 4 s 41 amd 2011 SL No. 168 s 3; 2011 SL No. 222 s 3; 2013 SL No. 41 s 4(2); 2013 SL No. 266 s 3; 2014 Act No. 42 s 24 Schedule 2A Dangerous drugs ins 2000 Act No. 28 s 26 sch amd 2002 SL No. 255 s 7(1); 2002 SL No. 368 s 6 om 2008 Act No. 4 s 42 Schedule 3 Specified quantities for particular dangerous drugs sections 4A, 8, 9, 125 and 134 of the Act Part 1 Quantities of non-steroid drugs Dangerous drug Quantity of dangerous drug Amphetamine 2.0g Barbituric Acid and any 5,5 disubstituted derivatives of barbituric acid whether or not further substituted at position 1 of the ring 50.0g 4-Bromo-2,5-dimethoxyamphetamine 0.5g 4-Bromo-2,5-dimethoxyphenethylamine 2.0g Cannabis 500.0g or, if the dangerous drug consists of plants the aggregate weight of which is less than 500.0g, 100 plants Cocaine 2.0g Codeine 10.0g N,N-Diethyltryptamine 2.0g 2,5-Dimethoxy-4-Ethylamphetamine (DOET) 2.0g 2,5-Dimethoxy-4-Methylamphetamine 2.0g N,N-Dimethyltryptamine 2.0g Fenethylline 2.0g Fentanyl 0.01g Gamma hydroxybutyric acid 2.0g Heroin 2.0g Hydromorphone 2.0g Lysergide 0.004g Methadone 2.0g Methcathinone 2.0g 5-Methoxy-3,4-Methylenedioxyamphetamine (MMDA) 2.0g 2-Methylamino-1-(3,4-methylenedioxyphenyl) butane (MBDB) 2.0g 4-Methylaminorex 2.0g Methylamphetamine 2.0g 3,4-Methylenedioxyethylamphetamine (MDEA) 2.0g 3,4-Methylenedioxymethamphetamine (MDMA) 2.0g 4-Methylthioamphetamine (4-MTA) 2.0g Moramide 2.0g Morphine 2.0g Opium 20.0g Paramethoxyamphetamine (PMA) 2.0g Paramethoxymethamphetamine (PMMA) 2.0g Pethidine 10.0g Phencyclidine 0.5g Psilocin 0.10g Psilocybin 0.10g Tetrahydrocannabinols including their alkyl homologues except where separately specified; and their corresponding carboxylic acids 2.0g 3,4,5-Trimethoxyamphetamine (TMA) 2.0g

Part 2 Quantities of steroid drugs Dangerous drug Whole weight of dangerous drug a dangerous drug mentioned in schedule 1, part 2 50.0g

sch hdg ins 1997 SL No. 459 s 5(1) amd 2013 SL No. 41 s 5(1) sch 3 (prev 1986 Act No. 36 sch 3) amd 1987 Act No. 53 s 12; 1989 Act No. 34 s 23 sub 1990 Act No. 88 s 3 sch amd 1996 Act No. 49 s 17 reloc 1996 Act No. 49 s 21 amd 1997 SL No. 303 s 4; 1997 SL No. 459 s 5(2)–(3); 1999 SL No. 41 s 4; 2001 SL No. 249 s 4; 2002 SL No. 255 s 7(1)–(2); 2002 SL No. 368 s 7; 2008 Act No. 4 s 43; 2009 SL No. 99 s 7; 2013 SL No. 41 s 5(2); 2014 Act No. 42 s 25 Schedule 4 Specified quantities for particular dangerous drugs sections 4A, 8, 9 and 134 of the Act Part 1 Quantities of non-steroid drugs Dangerous drug Quantity of dangerous drug Amphetamine 200.0g Cocaine 200.0g Heroin 200.0g Lysergide 0.4g Methylamphetamine 200.0g 3,4-Methylenedioxymethamphetamine (MDMA) 200.0g Paramethoxyamphetamine (PMA) 200.0g Paramethoxymethamphetamine (PMMA) 200.0g Phencyclidine 50.0g

Part 2 Quantities of steroid drugs Dangerous drug Whole weight of dangerous drug a dangerous drug mentioned in schedule 1, part 2 5000.0g

sch hdg ins 1997 SL No. 459 s 6(1) amd 2009 SL No. 99 s 8 sch 4 (prev 1986 Act No. 36 sch 4) amd 1996 Act No. 49 s 18 reloc 1996 Act No. 49 s 21 amd 1997 SL No. 459 s 6(2); 2001 SL No. 174 s 6; 2002 SL No. 255 s 7(1); 2008 Act No. 4 s 44; 2008 SL No. 144 s 4; 2013 SL No. 41 s 6; 2014 Act No. 42 s 26 Schedule 5 Dangerous drugs sections 4A, 124 and 134 of the Act Alprazolam Bromazepam Brotizolam Camazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate Clotiazepam Cloxazolam Delorazepam Diazepam Difenoxin other than in preparations containing 0.5mg or less of difenoxin and a quantity of atropine sulphate equivalent to not less than 5% of the dose of difenoxin per dosage unit Dihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of dihydrocodeine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of dihydrocodeine.

Diphenoxylate other than in preparations containing 2.5mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to not less than 1% of the dose of diphenoxylate per dosage unit Estazolam Ethyl Loflazepate Fludiazepam Flurazepam Halazepam Haloxazolam Ketazolam Loprazolam Lorazepam Lormetazepam Medazepam Midazolam Nimetazepam Nitrazepam Nordazepam Oxazepam Oxazolam Pholcodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of pholcodine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of pholcodine.

Pinazepam Prazepam Quazepam Temazepam Tetrazepam Triazolam Zolazapam sch hdg ins 1997 SL No. 459 s 7(1) amd 2009 SL No. 99 s 8 sch 5 (prev 1986 Act No. 36 sch 5) amd 1987 Act No. 53 s 13; 1996 Act No. 49 s 19 reloc 1996 Act No. 49 s 21 amd 1997 SL No. 459 s 7(2); 2002 SL No. 255 s 7(1), (3) sub 2008 Act No. 4 s 45 Schedule 6 Controlled substances sections 4, definition controlled substance , and 134 of the Act Substance Alternative name Acetic anhydride N-Acetylanthranilic acid 2-Acetamidobenzoic acid Allylbenzene 3-Phenyl-1-propene or 2-propenyl benzene 4-Aminobutanoic acid Piperidinic acid Ammonium formate Anthranilic acid 2-Aminobenzoic acid Benzaldehyde Benzyl bromide α-Bromotoluene Benzyl chloride α-Chlorotoluene Benzyl cyanide Boron tribromide Bromobenzene Phenylbromide Bromo safrole 1,4-Butanediol Tetramethylene glycol Calcium metal 1-Chlorophenyl-2-aminopropane Chromic acid Chromium trioxide Chromium (VI) oxide Ephedrine Ergometrine Ergonovine Ergotamine Ethanamine Monoethylamine N-Ethylephedrine Ethyl phenylacetate Benzeneacetic acid, ethyl ester N-Ethylpseudoephedrine Formamide Hydriodic acid Hydrogen iodide solution Hydrobromic acid Hydrogen bromide solution 4-Hydroxybutanal 4-Hydroxybutyraldehyde 4-Hydroxybutanoic acid lactone Gamma-butyrolactone 4-Hydroxybutanoic acid nitrile 4-Hydroxybutyronitrile 4-Hydroxypentanoic acid lactone Gamma-valerolactone 2-Hydroxytetrahydrofuran Tetrahydro-2-furanol Hypophosphorous acid Phosphinic acid Iodine Isosafrole 5-(1-Propenyl)-1,3-benzodioxole Lithium aluminium hydride Lithium metal Mercuric chloride Mercury bichloride or Mercury (II) chloride Methylamine Aminomethane or Monomethylamine Methylammonium salts 3,4-Methylenedioxyphenyl-2-propanone N-Methylephedrine N-Methylformamide Methyl phenylacetate Benzeneacetic acid, methyl ester N-Methylpseudoephedrine Nitroethane Norpseudoephedrine Palladium Phenylacetamide Phenylacetic acid Phenylacetonitrile Benzeneacetonitrile, Benzyl cyanide or Benzyl nitrile Phenylacetyl chloride 1-Phenyl-2-chloropropane 1-Phenyl-2-methylaminopropane 1-Phenyl-2-nitropropene 1-Phenyl-2-propanol Phenylpropanolamine Norephedrine 1-Phenyl-1-propanone Phenyl ethyl ketone or Propiophenone 1-Phenyl-2-propanone Benzyl methyl ketone or Phenylacetone 1-Phenyl-2-propanone oxime Phosphorous acid Phosphonic Acid Phosphorus (red or white) Piperidine Piperonal Heliotropine or 3,4-Methylenedioxybenzaldehyde Potassium metal Propionic anhydride Pseudoephedrine Pyridine 2-Pyrrolidone Gamma-butyrolactam Raney nickel Safrole 5-(2-Propenyl)-1,3-benzodioxide Sassafras oil Sodium borohydride Sodium metal Thionyl chloride Thorium

sch hdg amd 2009 SL No. 99 s 9 sch 6 (prev 1986 Act No. 36 sch 6) ins 1995 Act No. 18 s 8 amd 1996 Act No. 49 s 20 reloc 1996 Act No. 49 s 21 amd 1997 SL No. 459 s 8; 2002 SL No. 255 s 7(1) sub 2006 SL No. 71 s 5 Schedule 7 Conditions for particular persons authorised under part 4 section 10 (2) 1 Denaturer A denaturer must—

(a) keep industrial cannabis seed that has not been denatured in a securely locked place, other than when removing it to enable it to be denatured; and

(b) keep records of—

(i) the source and quantity of all industrial cannabis seed received for denaturing; and

(ii) when and by whom the industrial cannabis seed was delivered to the denaturer; and

(c) pay the chief executive’s reasonable costs of monitoring the denaturer’s activities to the extent to which they relate to the denaturing of industrial cannabis seed and the supply of processed cannabis to a manufacturer.

s 1 ins 1998 SL No. 348 s 5 sub 2002 SL No. 255 s 8 amd 2009 SL No. 99 s 10 2 DPI researcher A DPI researcher must—

(a) keep class A research cannabis plants the researcher is growing securely locked in a glasshouse; and

(b) grow class B research cannabis plants in an area that is fenced to delineate the area under production; and

(c) if the chief executive requires the researcher to erect signs indicating the presence of class B research cannabis at a fenced area, ensure the signs are erected as required by the chief executive; and

(d) keep industrial cannabis seed and class A and class B research cannabis seed in the researcher’s possession or under the researcher’s control locked in a secure place when not otherwise required—

(i) for use for planting; or

(ii) to be supplied to another person; and

(e) keep a register that includes the following information—

(i) the varieties or strains of cannabis plants and cannabis seed under the researcher’s control;

(ii) the source, quantity and delivery details for cannabis seed and plant varieties the researcher receives;

(iii) how, when and from whom the researcher received cannabis plants and seed delivered to the researcher;

(iv) if a carrier delivered the cannabis plants or seed to the researcher, the name of the person who delivered the plants or seed;

(v) if a researcher engages a carrier to deliver cannabis plants or seed to someone else—

(A) the name of the person to whom the plants or seed were given for delivery; and

(B) the name of the person to whom it is intended the plants or seed be supplied by the researcher.

s 2 ins 1998 SL No. 348 s 5 sub 2002 SL No. 255 s 8 3 Inspector An inspector who possesses industrial cannabis plants or seed or class A or class B research cannabis plants or seed for supplying them to someone else under part 4 must keep the plants or seed in a secure place until the inspector supplies them to the person. s 3 ins 1998 SL No. 348 s 5 sub 2002 SL No. 255 s 8 4 Seed supplier A seed supplier must—

(a) keep industrial cannabis seed in the supplier’s possession or under the supplier’s control locked in a secure place when not otherwise required for use for lawfully supplying the seed to a person mentioned in section 20; and

(b) keep records of the following information—

(i) the source and quantity of all industrial cannabis seed supplied to the supplier;

(ii) how, when and by whom industrial cannabis seed was delivered to the supplier;

(iii) if industrial cannabis seed is delivered to the supplier by a carrier—the name of the person who actually delivered the seed;

(iv) if the supplier supplies industrial cannabis seed to a carrier for delivery to a person—

(A) the name of the person to whom the seed was given for delivery; and

(B) the name of the person to whom it is intended the seed be supplied by the supplier;

(v) the name of each person to whom the supplier supplies industrial cannabis seed; and

(i) if the seed is cannabis seed harvested from an industrial cannabis plant—that fact; or

(ii) if the seed is certified cannabis seed—that fact; and

(d) ensure that each package of certified cannabis seed supplied by the seed supplier has a label on it, or attached to it, that describes the contents of the package as certified cannabis seed; and

(e) pack all industrial cannabis seed to be delivered to someone else by a carrier in a way that ensures, as far as reasonably practicable, seed can not be lost if the package is damaged.

s 4 ins 1998 SL No. 348 s 5 amd 1999 SL No. 235 s 3 sub 2002 SL No. 255 s 8 5 Analyst (1) This section applies if an analyst is engaged or employed to analyse a substance to determine its THC concentration. (2) The analyst must analyse the substance in a laboratory whose functions and operations are accredited by NATA for competence to undertake drug analysis. (3) The analyst must keep standard THC material in a securely locked place other than when the analyst is using the material in analysing the substance to determine its THC concentration. (4) The analyst must keep the substance in a securely locked place other than when the analyst is analysing the substance. (5) In this section— NATA means the National Association of Testing Authorities, Australia ABN 59 004 379 748. substance means a substance the analyst reasonably believes to be any of the following—

(a) industrial cannabis plants;

(b) class A or class B research cannabis plants;

s 5 ins 2002 SL No. 255 s 8 sch hdg ins 1998 SL No. 348 s 5 sch 7 sub 2002 SL No. 255 s 8 Schedule 8 Licence conditions section 29 (1)

1 A licensee who is authorised to produce class A research cannabis must—

(a) grow the cannabis in a glasshouse that is capable of being securely locked; and

(b) keep the glasshouse securely locked other than when the licensee or a person authorised by the licensee is performing functions directly associated with growing cannabis in the glasshouse.

2 A licensee who is authorised to produce class B research cannabis must—

(a) grow the cannabis in an area that is fenced to delineate the area under production; and

(b) if the chief executive requires the licensee to erect signs indicating the presence of class B research cannabis at a fenced area, ensure the signs are erected as required by the chief executive.

3 A licensee must keep cannabis seed in the licensee’s possession in a securely locked place, other than when the licensee uses the seed for a purpose that is authorised under the licensee’s licence.

4 A licensee must keep a register of the following—

(a) the strains or varieties of cannabis seed in the licensee’s possession;

(b) the strains or varieties of cannabis plants the licensee is growing.

5 A licensee must keep records of the following information—

(a) the source and quantity of all cannabis plants and seed supplied to the licensee;

(b) how, when and by whom plants or seed were delivered to the licensee;

(c) if cannabis plants or seed are delivered to the licensee by a carrier—the name of the person who actually delivered the plants or seed;

(d) if cannabis plants or seed are supplied to a carrier for delivery to a person—

(i) the name of the person to whom the plants or seed were given for delivery; and

(ii) the name of the person to whom it is intended the plants or seed be supplied by the carrier.

6 As soon as reasonably practicable after a licensee receives a package containing cannabis plants or seed that appears to have been tampered with, the licensee must inform an inspector or a police officer that the package appears to have been tampered with.

7 A licensee must pay the chief executive’s reasonable costs of monitoring activities performed under the licence, including any costs of an analyst conducting a laboratory analysis necessary to determine the concentration of THC in the leaves and flowering heads of cannabis plants in the licensee’s possession.

8 A category 2 researcher must allow an inspector to destroy, or supervise the destruction of, cannabis plants in the possession of the licensee that have been found, by an analyst conducting a laboratory analysis of a random sample of the leaves and flowering heads of the plants, to have a concentration of THC in their leaves and flowering heads of 3% or more.

9 A grower must allow an inspector to destroy, or supervise the destruction of, cannabis plants in the possession of the licensee that have been found, by an analyst conducting a laboratory analysis of a random sample of the leaves and flowering heads of the plants, to have a THC concentration in their leaves and flowering heads of more than 1%.

10 A licensee who proposes to supply industrial cannabis seed for sale by wholesale or retail must ensure—

(a) if the seed is cannabis seed harvested from an industrial cannabis plant—the package containing the seed has a label on it or attached to it that describes the contents of the package as cannabis seed harvested from an industrial cannabis plant; or

(b) if the seed is certified cannabis seed—the package containing the seed has a label on it, or attached to it, that describes the contents of the package as certified cannabis seed.

11 A category 2 researcher must ensure, as far as practicable, that cannabis seed supplied to the researcher by a person in another State or a foreign country is certified as seed that, if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of less than 3%.

12 A grower must ensure, as far as practicable, that cannabis seed supplied to the grower by a person in another State or a foreign country is certified as seed that, if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of not more than 0.5%.

ins 1998 SL No. 348 s 5 sub 1999 SL No. 235 s 4; 2000 SL No. 234 s 3; 2002 SL No. 255 s 8 Schedule 8A Gross weight of relevant substances for ss 9A, 9B, 9C and 9D of Act sections 9A, 9B, 9C, 9D and 134 of the Act Part 1 Substances that include their salts, derivatives and stereo-isomers 1 In this part, a reference to a substance includes a reference to—

(a) a salt, derivative or stereo-isomer of the substance; and

(b) a salt of a derivative or stereo-isomer of the substance.

Substance Alternative name Gross weight N-Acetylanthranilic acid 2-Acetamidobenzoic acid 0.1g Allylbenzene 3-Phenyl-1-propene or 2-propenyl benzene 0.1g 4-Aminobutanoic acid Piperidinic acid 0.1g Ammonium formate 0.1g Anthranilic acid 2-Aminobenzoic acid 0.1g Benzaldehyde 0.1g Benzyl bromide α-Bromotoluene 0.1g Benzyl chloride α-Chlorotoluene 0.1g Benzyl cyanide 0.1g Boron tribromide 0.1g Bromobenzene Phenylbromide 0.1g Bromo safrole 0.1g 1,4-Butanediol Tetramethylene glycol 0.1g 1-Chlorophenyl-2-aminopropane 0.1g Chromic acid 0.1g Chromium trioxide Chromium (VI) oxide 0.1g Ephedrine 0.1g Ergometrine Ergonovine 0.1g Ergotamine 0.1g Ethanamine Monoethylamine 0.1g N-Ethylephedrine 0.1g Ethyl phenylacetate Benzeneacetic acid, ethyl ester 0.1g N-Ethylpseudoephedrine 0.1g Formamide 0.1g 4-Hydroxybutanal 4-Hydroxybutyraldehyde 0.1g 4-Hydroxybutanoic acid lactone Gamma-butyrolactone 0.1g 4-Hydroxybutanoic acid nitrile 4-Hydroxybutyronitrile 0.1g 4-Hydroxypentanoic acid lactone Gamma-valerolactone 0.1g 2-Hydroxytetrahydrofuran Tetrahydro-2-furanol 0.1g Hypophosphorous acid Phosphinic acid 0.1g Isosafrole 5-(1-Propenyl)-1,3-benzodioxole 0.1g Lithium aluminium hydride 0.1g Mercuric chloride Mercury bichloride or Mercury (II) chloride 0.1g Methylamine Aminomethane or Monomethylamine 0.1g Methylammonium salts 0.1g 3,4-Methylenedioxyphenyl- 2-propanone 0.1g N-Methylephedrine 0.1g N-Methylformamide 0.1g Methyl phenylacetate Benzeneacetic acid, methyl ester 0.1g N-Methylpseudoephedrine 0.1g Nitroethane 0.1g Norpseudoephedrine 0.1g Palladium 0.1g Phenylacetamide 0.1g Phenylacetic acid 0.1g Phenylacetonitrile Benzeneacetonitrile, Benzyl cyanide or Benzyl nitrile 0.1g Phenylacetyl chloride 0.1g 1-Phenyl-2-chloropropane 0.1g 1-Phenyl-2-methylaminopropane 0.1g 1-Phenyl-2-nitropropene 0.1g 1-Phenyl-2-propanol 0.1g Phenylpropanolamine Norephedrine 0.1g 1-Phenyl-1-propanone Phenyl ethyl ketone or Propiophenone 0.1g 1-Phenyl-2-propanone Benzyl methyl ketone or Phenylacetone 0.1g 1-Phenyl-2-propanone oxime 0.1g Piperidine 0.1g Piperonal Heliotropine or 3,4-Methylenedioxybenzaldehyde 0.1g Propionic anhydride 0.1g Pseudoephedrine 50g or 1L Pyridine 0.1g 2-Pyrrolidone Gamma-butyrolactam 0.1g Raney nickel 0.1g Safrole 5-(2-Propenyl)-1,3-benzodioxide 0.1g Sassafras oil 0.1g Sodium borohydride 0.1g Thionyl chloride 0.1g Thorium 0.1g

Part 2 Substances that do not include their salts, derivatives and stereo-isomers 2 In this part, a reference to a substance does not include a reference to—

(a) a salt, derivative or stereo-isomer of the substance; and

(b) a salt of a derivative or stereo-isomer of the substance.

Substance Alternative name Gross weight Acetic anhydride 0.1g Calcium metal 0.1g Hydriodic acid Hydrogen iodide solution 0.1g Hydrobromic acid Hydrogen bromide solution 0.1g Iodine 0.1g Lithium metal 25g Phosphorous acid Phosphonic Acid 0.1g Phosphorus (red or white) 0.1g Potassium metal 0.1g Sodium metal 0.1g

sch hdg amd 2008 Act No. 4 s 46(1); 2013 Act No. 14 s 50 sch 8A ins 2006 SL No. 71 s 6 amd 2008 Act No. 4 s 46(2) Schedule 8B Things specified for ss 9A, 9B, 9C and 9D, and prescribed for s 134, of Act sections 9A, 9B, 9C, 9D and 134 of the Act

1 condenser

2 distillation head

3 heating mantle

4 manual or mechanical pill press, including a pill press under repair, a modification of a pill press and parts for a pill press

5 reaction vessel, including a reaction vessel under repair or a modification of a reaction vessel

6 rotary evaporator

7 splash head, including a splash head under repair or parts for a splash head

sch hdg amd 2008 Act No. 4 s 47(1); 2009 SL No. 99 s 11(1); 2013 Act No. 14 s 51 sch 8B ins 2006 SL No. 71 s 6 amd 2008 Act No. 4 s 47(2); 2009 SL No. 99 s 11(2) Schedule 8C Prohibited combinations of items sections 10B and 134 of the Act

1 A combination consisting of substances that are or contain—

(a) pseudoephedrine or its salts; and

(b) hypophosphorous acid; and

2 A combination consisting of substances that are or contain—

(a) pseudoephedrine or its salts; and

(b) hydriodic acid; and

3 A combination consisting of substances that are or contain—

(a) pseudoephedrine or its salts; and

(b) lithium metal; and

ins 2006 SL No. 71 s 6 Schedule 8D Relevant dangerous drugs sections 131 and 134 of the Act

amphetamine

methylamphetamine

ins 2006 SL No. 71 s 6 Schedule 9 Dictionary section 2 analyst means a person who holds an approval under the Health (Drugs and Poisons) Regulation 1996 to obtain, possess and use standard THC material to calibrate an analytical instrument used for analysing a substance to determine its THC concentration. carrier means a person who carries on a business of transporting a thing for delivery to the person to whom it is consigned, whether in Queensland or elsewhere, and whether the thing is transported by air, rail, road or sea. condenser means a cooling device for converting gases or vapours to liquid or solid form. def condenser ins 2006 SL No. 71 s 7 consigned includes addressed. consigned cannabis means any of the following—

(a) industrial cannabis plants;

(b) industrial cannabis seed;

(d) class B research cannabis;

(e) processed cannabis.

distillation head means an apparatus that—

(a) fits on top of a reaction vessel or a vessel that serves the same purpose as a reaction vessel; and

(b) connects to a condenser; and

def distillation head ins 2006 SL No. 71 s 7 DPI researcher means a public service officer—

(a) who is employed in the department within which the Agricultural Standards Act 1994 is administered; and

(b) whose duties include plant breeding; and

heating mantle means a device designed or adapted to heat a reaction vessel or a vessel that serves the same purpose as a reaction vessel. def heating mantle ins 2006 SL No. 71 s 7 occupier’s notice ... def occupier’s notice reloc 1998 SL No. 348 s 3(1) om 2002 SL No. 255 s 8 record of proceedings ... def record of proceedings reloc 1998 SL No. 348 s 3(1) om 2002 SL No. 255 s 8 search warrant ... def search warrant reloc 1998 SL No. 348 s 3(1) om 2002 SL No. 255 s 8 seed supplier means a person recognised as a seed supplier under section 27. splash head means an apparatus that fits between a reaction vessel, or a vessel that serves the same purpose as a reaction vessel, and a condenser and stops a heated substance contaminating the distillate. def splash head ins 2006 SL No. 71 s 7 standard THC material means THC of a known purity. supply—

(a) for part 3, see section 43A of the Act; or

(b) for part 4, does not include administer.

ins 1998 SL No. 348 s 5 sub 2002 SL No. 255 s 8